Boston Scientific Balance Sheet Health
Financial Health criteria checks 5/6
Boston Scientific has a total shareholder equity of $21.0B and total debt of $10.9B, which brings its debt-to-equity ratio to 51.9%. Its total assets and total liabilities are $38.1B and $17.1B respectively. Boston Scientific's EBIT is $2.8B making its interest coverage ratio 14.4. It has cash and short-term investments of $2.5B.
Key information
51.9%
Debt to equity ratio
US$10.88b
Debt
| Interest coverage ratio | 14.4x |
| Cash | US$2.50b |
| Equity | US$20.96b |
| Total liabilities | US$17.12b |
| Total assets | US$38.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($8.8B) exceed its short term liabilities ($5.9B).
Long Term Liabilities: BSX's short term assets ($8.8B) do not cover its long term liabilities ($11.2B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (40%) is considered satisfactory.
Reducing Debt: BSX's debt to equity ratio has reduced from 112.2% to 51.9% over the past 5 years.
Debt Coverage: BSX's debt is well covered by operating cash flow (27%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (14.4x coverage).